4-(1,2,5,6-TETRAHYDRO-1-ALKYL-3-PYRIDINYL)-2-THIAZOLAMINES - A NOVEL CLASS OF COMPOUNDS WITH CENTRAL DOPAMINE AGONIST PROPERTIES

被引:249
作者
JAEN, JC [1 ]
WISE, LD [1 ]
CAPRATHE, BW [1 ]
TECLE, H [1 ]
BERGMEIER, S [1 ]
HUMBLET, CC [1 ]
HEFFNER, TG [1 ]
MELTZER, LT [1 ]
PUGSLEY, TA [1 ]
机构
[1] WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT PHARMACOL, ANN ARBOR, MI 48105 USA
关键词
D O I
10.1021/jm00163a051
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The design, synthesis, and pharmacological properties of a novel type of 4-(1, 2, 5, 6-tetrahydro-l-alkyl-3-pyridinyl)-2-thiazolamine with dopaminergic properties are described. In particular, 4-(1, 2, 5, 6-tetrahydro-l-propyl-3-pyridinyl)-2-thiazolamine (4c, PD 118440) and its allyl analogue (4c, PD 120697) have been identified as orally active dopamine (DA) agonists with pronounced central nervous system effects in tests that include [3H]-haloperidol and [3H]-N-propylnorapomorphine binding, inhibition of striatal DA synthesis, inhibition of DA neuronal firing, inhibition of spontaneous locomotor activity, and reversal of reserpine-induced depression in rats. The DA autoreceptor selectivity of these heterocyclic analogues of 3-(l-propyl-3-piperidinyl)phenol (3-PPP) was also evaluated. In this series, DA agonist activity was found to be highly dependent on the size of the N-alkyl substituent, the saturation level of the six-membered ring, and the mode of attachment of the 2-aminothiazole ring. © 1990, American Chemical Society. All rights reserved.
引用
收藏
页码:311 / 317
页数:7
相关论文
共 61 条
[1]  
ANDEN NE, 1983, ACTA PHARMACOL TOX, V52, P51
[2]   DOPAMINE AND NORADRENALINE RECEPTOR STIMULATION - REVERSAL OF RESERPINE-INDUCED SUPPRESSION OF MOTOR ACTIVITY [J].
ANDEN, NE ;
STROMBOM, U ;
SVENSSON, TH .
PSYCHOPHARMACOLOGIA, 1973, 29 (04) :289-298
[3]   EFFECTS OF S (+)-3-PHENETHYL-PP, A PUTATIVE DOPAMINE AUTORECEPTOR AGONIST WITH GREATER AUTORECEPTOR SELECTIVITY THAN 3-PP ENANTIOMERS [J].
ARNT, J ;
BOGESO, KP ;
HYTTEL, J ;
LARSEN, JJ ;
SVENDSEN, O .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 102 (01) :91-99
[4]   RELATIVE DOPAMINE D1 AND D2 RECEPTOR AFFINITY AND EFFICACY DETERMINE WHETHER DOPAMINE AGONISTS INDUCE HYPERACTIVITY OR ORAL STEREOTYPY IN RATS [J].
ARNT, J ;
BOGESO, KP ;
HYTTEL, J ;
MEIER, E .
PHARMACOLOGY & TOXICOLOGY, 1988, 62 (03) :121-130
[5]   DOPAMINE D-1 RECEPTOR AGONISTS COMBINED WITH THE SELECTIVE D-2 AGONIST QUINPIROLE FACILITATE THE EXPRESSION OF ORAL STEREOTYPED BEHAVIOR IN RATS [J].
ARNT, J ;
HYTTEL, J ;
PERREGAARD, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 133 (02) :137-145
[6]   DRUG DESIGN VIA PHARMACOPHORE IDENTIFICATION - DOPAMINERGIC ACTIVITY OF 3H-BENZ[E]INDOL-8-AMINES AND THEIR MODE OF INTERACTION WITH THE DOPAMINE RECEPTOR [J].
ASSELIN, AA ;
HUMBER, LG ;
VOITH, K ;
METCALF, G .
JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (05) :648-654
[7]   BICYCLIC AND TRICYCLIC ERGOLINE PARTIAL STRUCTURES - RIGID 3-(2-AMINOETHYL)PYRROLES AND 3-(2-AMINOETHYL)PYRAZOLE AND 4-(2-AMINOETHYL)PYRAZOLE AS DOPAMINE AGONISTS [J].
BACH, NJ ;
KORNFELD, EC ;
JONES, ND ;
CHANEY, MO ;
DORMAN, DE ;
PASCHAL, JW ;
CLEMENS, JA ;
SMALSTIG, EB .
JOURNAL OF MEDICINAL CHEMISTRY, 1980, 23 (05) :481-491
[8]   N,N-DISUBSTITUTED 2-AMINOTETRALINS ARE POTENT D-2 DOPAMINE RECEPTOR AGONISTS [J].
BEAULIEU, M ;
ITOH, Y ;
TEPPER, P ;
HORN, AS ;
KEBABIAN, JW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 105 (1-2) :15-21
[9]  
BHAIRD NN, 1985, BIOCHEM PHARMACOL, V34, P3601
[10]  
BLACKWELL RE, 1983, FERTIL STERIL, V39, P744